biostudies-literatureBarbato AAssociazione Italiana per la Ricerca sul CancroPOR CAMPANIA FESR 2014/2020 "Genomica e Terapia"H2020 Marie Skłodowska-Curie Actions1801https://www.ebi.ac.uk/biostudies/studies/S-EPMC7918089biostudies-literatureUnknown22(4)MicroRNAs (miRNAs) are attractive therapeutic targets and promising candidates as molecular biomarkers for various therapy-resistant tumors. However, the association between miRNAs and drug resistance in melanoma remains to be elucidated. We used an integrative genomic analysis to comprehensively study the miRNA expression profiles of drug-resistant melanoma patients and cell lines. MicroRNA-181a and -181b (miR181a/b) were identified as the most significantly down-regulated miRNAs in resistant melanoma patients and cell lines. Re-establishment of miR-181a/b expression reverses the resistance of melanoma cells to the BRAF inhibitor dabrafenib. Introduction of miR-181 mimics markedly decreases the expression of TFAM in A375 melanoma cells resistant to BRAF inhibitors. Furthermore, melanoma gInternational journal of molecular sciencesIntegrated Genomics Identifies miR-181/TFAM Pathway as a Critical Driver of Drug Resistance in Melanoma.PMC7918089GENTER80092417711/2015Indrieri AMassa FRusso GAscierto PABarbato ACacchiarelli DMadonna GBrillante SSalati MDe Cegli RRiccardo SCapone MD'Alterio RFranco BVolpe MCarrella SRusso ACarotenuto PIuliano AfalseIntegrated Genomics Identifies miR-181/TFAM Pathway as a Critical Driver of Drug Resistance in Melanoma.MicroRNAs (miRNAs) are attractive therapeutic targets and promising candidates as molecular biomarkers for various therapy-resistant tumors. However, the association between miRNAs and drug resistance in melanoma remains to be elucidated. We used an integrative genomic analysis to comprehensively study the miRNA expression profiles of drug-resistant melanoma patients and cell lines. MicroRNA-181a and -181b (miR181a/b) were identified as the most significantly down-regulated miRNAs in resistant melanoma patients and cell lines. Re-establishment of miR-181a/b expression reverses the resistance of melanoma cells to the BRAF inhibitor dabrafenib. Introduction of miR-181 mimics markedly decreases the expression of TFAM in A375 melanoma cells resistant to BRAF inhibitors. Furthermore, melanoma g2021-01-01T00:00:00Z2021 Feb2026-04-18T01:23:23.904Z2021-03-05T08:57:09ZS-EPMC79180893367036510.3390/ijms22041801